Dr. Maneesh Paul, the Lead Co-Inventor and Program Director of 𝘌𝘯𝘮𝘦𝘵𝘢𝘻𝘰𝘣𝘢𝘤𝘵𝘢𝘮, is a clinical microbiologist who pursued basic and applied research discovering novel anti-infectives and characterising several microbial genes and proteins. He has translated scientific accomplishments and leadership through patents and publications.

He received his master’s degree in medical microbiology from 𝘒𝘢𝘴𝘵𝘶𝘳𝘣𝘢 𝘔𝘦𝘥𝘪𝘤𝘢𝘭 𝘊𝘰𝘭𝘭𝘦𝘨𝘦: 𝘔𝘈𝘏𝘌 and went on to undertake research for his 𝘗𝘩.𝘋. 𝘧𝘳𝘰𝘮 𝘎𝘶𝘭𝘣𝘢𝘳𝘨𝘢 𝘜𝘯𝘪𝘷𝘦𝘳𝘴𝘪𝘵𝘺, supported by 𝘑𝘦𝘢𝘯-𝘊𝘭𝘢𝘪𝘳𝘦 𝘓𝘦𝘦 𝘰𝘧 𝘏𝘢𝘳𝘷𝘢𝘳𝘥 𝘔𝘦𝘥𝘪𝘤𝘢𝘭 𝘚𝘤𝘩𝘰𝘰𝘭, 𝘉𝘰𝘴𝘵𝘰𝘯, 𝘜𝘚𝘈.

As a Post-Doctoral Fellow at Johns Hopkins School of Medicine, USA, he was trained in infectious diseases, specifically in molecular mechanisms of the pathogenesis of neonatal microbial meningitis, especially 𝘌. 𝘤𝘰𝘭𝘪 (𝘸𝘪𝘵𝘩 𝘋𝘳. 𝘒𝘸𝘢𝘯𝘨 𝘚𝘪𝘬 𝘒𝘪𝘮), 𝘢𝘯𝘥 𝘔. 𝘵𝘶𝘣𝘦𝘳𝘤𝘶𝘭𝘰𝘴𝘪𝘴 (𝘢𝘵 𝘑𝘰𝘩𝘯𝘴 𝘏𝘰𝘱𝘬𝘪𝘯𝘴 𝘉𝘭𝘰𝘰𝘮𝘣𝘦𝘳𝘨 𝘚𝘤𝘩𝘰𝘰𝘭 𝘰𝘧 𝘗𝘶𝘣𝘭𝘪𝘤 𝘏𝘦𝘢𝘭𝘵𝘩 𝘸𝘪𝘵𝘩 𝘋𝘳. 𝘞𝘪𝘭𝘭𝘪𝘢𝘮 𝘉𝘪𝘴𝘩𝘢𝘪).

Dr. Paul was also a Post-Doctoral Fellow with 𝘜𝘮𝘦å 𝘜𝘯𝘪𝘷𝘦𝘳𝘴𝘪𝘵𝘺, 𝘚𝘸𝘦𝘥𝘦𝘯, 𝘴𝘵𝘶𝘥𝘺𝘪𝘯𝘨 𝘵𝘩𝘦 𝘳𝘰𝘭𝘦 𝘰𝘧 𝘈. 𝘢𝘤𝘵𝘪𝘯𝘰𝘮𝘺𝘤𝘦𝘵𝘦𝘮𝘤𝘰𝘮𝘪𝘵𝘢𝘯𝘴 in the pathogenesis of atherosclerosis, collaborating with 𝘋𝘳. 𝘊𝘢𝘴𝘦𝘺 𝘊𝘩𝘦𝘯 (𝘜𝘯𝘪𝘷𝘦𝘳𝘴𝘪𝘵𝘺 𝘰𝘧 𝘚𝘰𝘶𝘵𝘩𝘦𝘳𝘯 𝘊𝘢𝘭𝘪𝘧𝘰𝘳𝘯𝘪𝘢, 𝘜𝘚𝘈), 𝘋𝘳. 𝘚𝘤𝘰𝘵𝘵 𝘏𝘶𝘭𝘵𝘨𝘳𝘦𝘯 (𝘜𝘯𝘪𝘷𝘦𝘳𝘴𝘪𝘵𝘺 𝘰𝘧 𝘞𝘢𝘴𝘩𝘪𝘯𝘨𝘵𝘰𝘯, 𝘚𝘵. 𝘓𝘰𝘶𝘪𝘴, 𝘜𝘚𝘈), 𝘋𝘳. 𝘚𝘵𝘢𝘧𝘧𝘢𝘯 𝘕𝘰𝘳𝘮𝘢𝘳𝘬 (𝘒𝘢𝘳𝘰𝘭𝘪𝘯𝘴𝘬𝘢 𝘐𝘯𝘴𝘵𝘪𝘵𝘶𝘵𝘦, 𝘚𝘵𝘰𝘤𝘬𝘩𝘰𝘭𝘮, 𝘚𝘸𝘦𝘥𝘦𝘯), 𝘋𝘳. 𝘗𝘪𝘳𝘬𝘬𝘰 𝘗𝘶𝘴𝘴𝘪𝘯𝘦𝘯 (𝘜𝘯𝘪𝘷𝘦𝘳𝘴𝘪𝘵𝘺 𝘰𝘧 𝘏𝘦𝘭𝘴𝘪𝘯𝘬𝘪, 𝘍𝘪𝘯𝘭𝘢𝘯𝘥) and many others.

Dr. Paul was the 𝘖𝘙𝘐𝘚𝘌 𝘍𝘦𝘭𝘭𝘰𝘸 𝘸𝘪𝘵𝘩 𝘋𝘳. 𝘔𝘢𝘳𝘨𝘢𝘳𝘦𝘵 𝘉𝘢𝘴𝘩 𝘢𝘵 𝘵𝘩𝘦 𝘊𝘦𝘯𝘵𝘦𝘳 𝘧𝘰𝘳 𝘉𝘪𝘰𝘭𝘰𝘨𝘪𝘤𝘴 𝘌𝘷𝘢𝘭𝘶𝘢𝘵𝘪𝘰𝘯 𝘢𝘯𝘥 𝘙𝘦𝘴𝘦𝘢𝘳𝘤𝘩, 𝘜𝘚𝘍𝘋𝘈, 𝘔𝘋, 𝘜𝘚𝘈, working on reverse vaccinology of 𝘕. 𝘮𝘦𝘯𝘪𝘯𝘨𝘪𝘵𝘪𝘥𝘪𝘴, 𝘢𝘯𝘥 𝘢𝘯 𝘐𝘯𝘥𝘶𝘴𝘵𝘳𝘪𝘢𝘭 𝘍𝘦𝘭𝘭𝘰𝘸 𝘪𝘯 𝘵𝘩𝘦 𝘢𝘯𝘵𝘪-𝘪𝘯𝘧𝘦𝘤𝘵𝘪𝘷𝘦𝘴 𝘯𝘦𝘸 𝘥𝘳𝘶𝘨 𝘥𝘪𝘴𝘤𝘰𝘷𝘦𝘳𝘺 𝘱𝘳𝘰𝘨𝘳𝘢𝘮 𝘢𝘵 𝘋𝘳. 𝘙𝘦𝘥𝘥𝘺’𝘴 𝘓𝘢𝘣𝘰𝘳𝘢𝘵𝘰𝘳𝘪𝘦𝘴 𝘓𝘵𝘥., 𝘐𝘯𝘥𝘪𝘢.

Since 2006, Dr. Paul has led the anti-infectives discovery research group in Senior Leadership Positions at 𝘖𝘳𝘤𝘩𝘪𝘥 𝘗𝘩𝘢𝘳𝘮𝘢, 𝘐𝘯𝘥𝘪𝘢, and co-invented several pre-clinical candidates in the anti-bacterial and anti-fungal space, including leading the 𝘌𝘯𝘮𝘦𝘵𝘢𝘻𝘰𝘣𝘢𝘤𝘵𝘢𝘮 program and out-licensing it at Phase 1 to Allecra Therapeutics GmbH. The molecule is now approved by the 𝘜𝘚𝘍𝘋𝘈, 𝘌𝘔𝘈, 𝘜𝘒𝘔𝘏𝘙𝘈, 𝘢𝘯𝘥 𝘋𝘊𝘎𝘐 (𝘐𝘯𝘥𝘪𝘢) for marketing (2024),the first India-invented NCE to receive such approvals from all four major regulatory agencies.

As the Chief Scientific Officer, he led post-graduate evidence-based medical research at 𝘚𝘵. 𝘔𝘢𝘳𝘵𝘩𝘢’𝘴 𝘏𝘰𝘴𝘱𝘪𝘵𝘢𝘭, 𝘐𝘯𝘥𝘪𝘢, in addition to continuing to advise several companies (2013–2018).

He led trans-disciplinary research at 𝘈𝘤𝘩𝘢𝘳𝘺𝘢 𝘎𝘳𝘰𝘶𝘱 𝘰𝘧 𝘐𝘯𝘴𝘵𝘪𝘵𝘶𝘵𝘪𝘰𝘯𝘴, 𝘉𝘦𝘯𝘨𝘢𝘭𝘶𝘳𝘶 (2018–2022), and, as the Campus Director, enabled the process of 𝘈𝘤𝘩𝘢𝘳𝘺𝘢 Institutes becoming a research-based campus (proposed university) of academic excellence.

He became an AMR stewardship champion at the 𝘎𝘰𝘳𝘥𝘰𝘯 𝘊𝘰𝘯𝘧𝘦𝘳𝘦𝘯𝘤𝘦 (𝘊𝘪𝘰𝘤𝘤𝘰, 𝘐𝘵𝘢𝘭𝘺) through the Antibiotic Action initiative led by 𝘋𝘳. 𝘓𝘢𝘶𝘳𝘢 𝘗𝘪𝘥𝘥𝘰𝘤𝘬.

He has served as a member of the AMR Committee (until 2022) of the 𝘐𝘯𝘧𝘦𝘤𝘵𝘪𝘰𝘶𝘴 𝘋𝘪𝘴𝘦𝘢𝘴𝘦𝘴 𝘚𝘰𝘤𝘪𝘦𝘵𝘺 𝘰𝘧 𝘈𝘮𝘦𝘳𝘪𝘤𝘢 (𝘐𝘋𝘚𝘈), 𝘜𝘚𝘈.

He is currently (2024–2026) appointed as a member of the Strategic Advisory Committee of the 𝘜𝘒 𝘙𝘦𝘴𝘦𝘢𝘳𝘤𝘩 𝘢𝘯𝘥 𝘐𝘯𝘯𝘰𝘷𝘢𝘵𝘪𝘰𝘯 (𝘜𝘒𝘙𝘐) 𝘪𝘯𝘪𝘵𝘪𝘢𝘵𝘪𝘷𝘦 𝘪𝘯 𝘈𝘯𝘵𝘪𝘮𝘪𝘤𝘳𝘰𝘣𝘪𝘢𝘭 𝘙𝘦𝘴𝘪𝘴𝘵𝘢𝘯𝘤𝘦 – 𝘗𝘈𝘊𝘌-𝘈𝘔𝘙 (𝘗𝘢𝘵𝘩𝘸𝘢𝘺𝘴 𝘵𝘰 𝘈𝘯𝘵𝘪𝘮𝘪𝘤𝘳𝘰𝘣𝘪𝘢𝘭 𝘊𝘭𝘪𝘯𝘪𝘤𝘢𝘭 𝘌𝘧𝘧𝘪𝘤𝘢𝘤𝘺).

He founded 𝘔𝘪𝘤𝘳𝘰𝘷𝘪𝘰𝘮𝘢 to address the challenges of AMR through innovation and community antimicrobial stewardship through 𝘈𝘔𝘙𝘈𝘊𝘌 (𝘈𝘔𝘙 𝘈𝘤𝘵𝘪𝘰𝘯 𝘊𝘰𝘭𝘭𝘢𝘣𝘰𝘳𝘢𝘵𝘪𝘷𝘦 𝘌𝘯𝘨𝘢𝘨𝘦𝘮𝘦𝘯𝘵). Microvioma is primarily the consulting arm of Dr. Paul, where his focus is on working with biotech and pharma companies or individuals in finding innovative solutions to address AMR (drug discovery and diagnostics).

Former Trustee, Foundation for Indian Biotech MSMEs and Startups (IBioM).